BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory


1/28/2013 9:26:45 AM

TORRANCE, Calif., Jan. 25, 2013 /PRNewswire/ -- Emmaus Life Sciences, Inc., a company dedicated to the discovery, development and commercialization of innovative and cost effective treatments and therapies for rare diseases, today issued the following statement in response to an announcement issued January 24, 2013 by AFH Holding & Advisory, LLC.:

AFH Holding & Advisory and its counsel have misrepresented the nature and effect of a recent ruling by the Los Angeles Superior Court. Far from "preventing [Emmaus] from pursuing a lawsuit it had filed" against AFH Holding & Advisory, the court's decision merely stayed the proceedings in California and held that the claims are contractually required to be brought in Delaware, where Emmaus is currently engaged in litigation against AFH Holding & Advisory and its principal Amir Heshmatpour. The court's narrow and technical ruling in no way addressed the merits of Emmaus's claims, which management believes are strongly supported by the evidence. Neither this nor any further attempt by AFH Holding & Advisory to litigate by press release will dissuade Emmaus from pursuing its claims in whatever forum is appropriate for their adjudication.

About Emmaus Life Sciences
Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com

SOURCE Emmaus Life Sciences, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES